La Jolla Pharmaceutical Company Receives Orphan Designation from FDA for LJPC-0118 (Artesunate) for the Treatment of Malaria

Stock Information for La Jolla Pharmaceutical Company

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About La Jolla Pharmaceutical Company

Innoviva Completes Acquisition of La Jolla Pharmaceutical
SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, VIVO, LJPC, SMED
SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations
LJPC Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of La Jolla Pharmaceutical Company Is Fair to Shareholders
INVESTIGATION ALERT: Halper Sadeh LLP Investigates ZEN, LJPC, VIVO, PCSB
Lifshitz Law PLLC Announces Investigation of RFP, LJPC, ZEN and NEOG
The M&A Class Action Firm is Investigating the Mergers of NEOG, LJPC, and XPOA

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.